Cargando…
End-stage kidney disease in patients with clinically manifest vascular disease; incidence and risk factors: results from the UCC-SMART cohort study
BACKGROUND: Patients with cardiovascular disease (CVD) are at increased risk of end-stage kidney disease (ESKD). Insights into the incidence and role of modifiable risk factors for end-stage kidney disease may provide means for prevention in patients with cardiovascular disease. METHODS: We included...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494654/ https://www.ncbi.nlm.nih.gov/pubmed/33713332 http://dx.doi.org/10.1007/s40620-021-00996-1 |
_version_ | 1784579359835684864 |
---|---|
author | Østergaard, Helena Bleken Westerink, Jan Verhaar, Marianne C. Bots, Michiel L. Asselbergs, Folkert W. de Borst, Gert J. Kappelle, L. Jaap Visseren, Frank L. J. van der Leeuw, Joep |
author_facet | Østergaard, Helena Bleken Westerink, Jan Verhaar, Marianne C. Bots, Michiel L. Asselbergs, Folkert W. de Borst, Gert J. Kappelle, L. Jaap Visseren, Frank L. J. van der Leeuw, Joep |
author_sort | Østergaard, Helena Bleken |
collection | PubMed |
description | BACKGROUND: Patients with cardiovascular disease (CVD) are at increased risk of end-stage kidney disease (ESKD). Insights into the incidence and role of modifiable risk factors for end-stage kidney disease may provide means for prevention in patients with cardiovascular disease. METHODS: We included 8402 patients with stable cardiovascular disease. Incidence rates (IRs) for end-stage kidney disease were determined stratified according to vascular disease location. Cox proportional hazard models were used to assess the risk of end-stage kidney disease for the different determinants. RESULTS: Sixty-five events were observed with a median follow-up of 8.6 years. The overall incidence rate of end-stage kidney disease was 0.9/1000 person-years. Patients with polyvascular disease had the highest incidence rate (1.8/1000 person-years). Smoking (Hazard ratio (HR) 1.87; 95% CI 1.10–3.19), type 2 diabetes (HR 1.81; 95% CI 1.05–3.14), higher systolic blood pressure (HR 1.37; 95% CI 1.24–1.52/10 mmHg), lower estimated glomerular filtration rate (eGFR) (HR 2.86; 95% CI 2.44–3.23/10 mL/min/1.73 m(2)) and higher urine albumin/creatinine ratio (uACR) (HR 1.19; 95% CI 1.15–1.23/10 mg/mmol) were independently associated with elevated risk of end-stage kidney disease. Body mass index (BMI), waist circumference, non-HDL-cholesterol and exercise were not independently associated with risk of end-stage kidney disease. CONCLUSIONS: Incidence of end-stage kidney disease in patients with cardiovascular disease varies according to vascular disease location. Several modifiable risk factors for end-stage kidney disease were identified in patients with cardiovascular disease. These findings highlight the potential of risk factor management in patients with manifest cardiovascular disease. GRAPHIC ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40620-021-00996-1. |
format | Online Article Text |
id | pubmed-8494654 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-84946542021-10-15 End-stage kidney disease in patients with clinically manifest vascular disease; incidence and risk factors: results from the UCC-SMART cohort study Østergaard, Helena Bleken Westerink, Jan Verhaar, Marianne C. Bots, Michiel L. Asselbergs, Folkert W. de Borst, Gert J. Kappelle, L. Jaap Visseren, Frank L. J. van der Leeuw, Joep J Nephrol Original Article BACKGROUND: Patients with cardiovascular disease (CVD) are at increased risk of end-stage kidney disease (ESKD). Insights into the incidence and role of modifiable risk factors for end-stage kidney disease may provide means for prevention in patients with cardiovascular disease. METHODS: We included 8402 patients with stable cardiovascular disease. Incidence rates (IRs) for end-stage kidney disease were determined stratified according to vascular disease location. Cox proportional hazard models were used to assess the risk of end-stage kidney disease for the different determinants. RESULTS: Sixty-five events were observed with a median follow-up of 8.6 years. The overall incidence rate of end-stage kidney disease was 0.9/1000 person-years. Patients with polyvascular disease had the highest incidence rate (1.8/1000 person-years). Smoking (Hazard ratio (HR) 1.87; 95% CI 1.10–3.19), type 2 diabetes (HR 1.81; 95% CI 1.05–3.14), higher systolic blood pressure (HR 1.37; 95% CI 1.24–1.52/10 mmHg), lower estimated glomerular filtration rate (eGFR) (HR 2.86; 95% CI 2.44–3.23/10 mL/min/1.73 m(2)) and higher urine albumin/creatinine ratio (uACR) (HR 1.19; 95% CI 1.15–1.23/10 mg/mmol) were independently associated with elevated risk of end-stage kidney disease. Body mass index (BMI), waist circumference, non-HDL-cholesterol and exercise were not independently associated with risk of end-stage kidney disease. CONCLUSIONS: Incidence of end-stage kidney disease in patients with cardiovascular disease varies according to vascular disease location. Several modifiable risk factors for end-stage kidney disease were identified in patients with cardiovascular disease. These findings highlight the potential of risk factor management in patients with manifest cardiovascular disease. GRAPHIC ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40620-021-00996-1. Springer International Publishing 2021-03-13 2021 /pmc/articles/PMC8494654/ /pubmed/33713332 http://dx.doi.org/10.1007/s40620-021-00996-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Østergaard, Helena Bleken Westerink, Jan Verhaar, Marianne C. Bots, Michiel L. Asselbergs, Folkert W. de Borst, Gert J. Kappelle, L. Jaap Visseren, Frank L. J. van der Leeuw, Joep End-stage kidney disease in patients with clinically manifest vascular disease; incidence and risk factors: results from the UCC-SMART cohort study |
title | End-stage kidney disease in patients with clinically manifest vascular disease; incidence and risk factors: results from the UCC-SMART cohort study |
title_full | End-stage kidney disease in patients with clinically manifest vascular disease; incidence and risk factors: results from the UCC-SMART cohort study |
title_fullStr | End-stage kidney disease in patients with clinically manifest vascular disease; incidence and risk factors: results from the UCC-SMART cohort study |
title_full_unstemmed | End-stage kidney disease in patients with clinically manifest vascular disease; incidence and risk factors: results from the UCC-SMART cohort study |
title_short | End-stage kidney disease in patients with clinically manifest vascular disease; incidence and risk factors: results from the UCC-SMART cohort study |
title_sort | end-stage kidney disease in patients with clinically manifest vascular disease; incidence and risk factors: results from the ucc-smart cohort study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494654/ https://www.ncbi.nlm.nih.gov/pubmed/33713332 http://dx.doi.org/10.1007/s40620-021-00996-1 |
work_keys_str_mv | AT østergaardhelenableken endstagekidneydiseaseinpatientswithclinicallymanifestvasculardiseaseincidenceandriskfactorsresultsfromtheuccsmartcohortstudy AT westerinkjan endstagekidneydiseaseinpatientswithclinicallymanifestvasculardiseaseincidenceandriskfactorsresultsfromtheuccsmartcohortstudy AT verhaarmariannec endstagekidneydiseaseinpatientswithclinicallymanifestvasculardiseaseincidenceandriskfactorsresultsfromtheuccsmartcohortstudy AT botsmichiell endstagekidneydiseaseinpatientswithclinicallymanifestvasculardiseaseincidenceandriskfactorsresultsfromtheuccsmartcohortstudy AT asselbergsfolkertw endstagekidneydiseaseinpatientswithclinicallymanifestvasculardiseaseincidenceandriskfactorsresultsfromtheuccsmartcohortstudy AT deborstgertj endstagekidneydiseaseinpatientswithclinicallymanifestvasculardiseaseincidenceandriskfactorsresultsfromtheuccsmartcohortstudy AT kappelleljaap endstagekidneydiseaseinpatientswithclinicallymanifestvasculardiseaseincidenceandriskfactorsresultsfromtheuccsmartcohortstudy AT visserenfranklj endstagekidneydiseaseinpatientswithclinicallymanifestvasculardiseaseincidenceandriskfactorsresultsfromtheuccsmartcohortstudy AT vanderleeuwjoep endstagekidneydiseaseinpatientswithclinicallymanifestvasculardiseaseincidenceandriskfactorsresultsfromtheuccsmartcohortstudy AT endstagekidneydiseaseinpatientswithclinicallymanifestvasculardiseaseincidenceandriskfactorsresultsfromtheuccsmartcohortstudy |